CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acceleron Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acceleron Pharma Inc
128 Sidney St
Phone: (617) 649-9200p:617 649-9200 CAMBRIDGE, MA  02139-4239  United States Fax: (617) 649-9988f:617 649-9988
This company was Merged or Acquired on 11/22/2021.
This company ceased filing statements with the SEC on 12/2/2021.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. Its therapeutic areas include pulmonary and hematology. Its pulmonary program, Sotatercept, is a receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC). It generates multiple Fc-fusion protein ligand traps, IntelliTrap platform technology and a pipeline of clinical and preclinical therapeutic candidates targeting mechanisms underlying serious and rare diseases.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202112/31/2020YesYes--Yes

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Francois E.Nader 64 3/1/2015 12/12/2014
President, Chief Executive Officer, Director Habib J.Dable 51 12/1/2016 12/1/2016
Chief Financial Officer, Senior Vice President, Treasurer Kevin F.Mclaughlin 64 11/1/2010 11/1/2010
7 additional Officers and Directors records available in full report.

Business Names
Business Name
Acceleron Holding Ltd.
Acceleron Pharma Switzerland AG
Acceleron Securities Corp.
XLRN

General Information
Number of Employees: 312 (As of 12/31/2020)
Outstanding Shares: 61,130,687 (As of 9/30/2021)
Shareholders: 48
Stock Exchange: NASD
Federal Tax Id: 270072226
Fax Number: (617) 649-9988


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 3, 2024